The Perils and Promise of Strategic Partnering with CROs

Strategic partnerships have long been a major feature of the pharmaceutical industry. In-licensing, out-licensing, joint research, and co-development arrangements between and among biopharmaceutical companies, and with academic research institutions, abound. Approximately 33% of drugs in the pipelines of the top ten pharmaceutical companies were initially developed elsewhere, according to a 2014 WSJ article by Jonathan D. Rockoff. And according to Vantage’s recent alliance benchmarking study, over 80% of bio-pharma respondents report increased alliance activity compared to five years ago.

Download The Article